AML transformation in 56 patients with Ph− MPD in two well defined populations

Khadija Abdulkarim(Sahlgrenska University Hospital), Björn Andréasson(NU Hospital Group), François Girodon(Inserm), Peter Johansson(Linköping University), Marc Maynadié(Université de Bourgogne), Emeline Bovet(Université de Bourgogne), Paule‐Marie Carli(Hôpital Purpan), Jack Kutti(Sahlgrenska University Hospital)
European Journal Of Haematology
October 8, 2008
10.1111/j.1600-0609.2008.01163.x
Cited by 78

Related Papers

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
|Journal of Clinical Oncology|2012|461
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients
|Blood|2011|340
Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project
|JNCI Monographs|2014|334
A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment
|Blood|2012|270
Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms
|Journal of Clinical Oncology|2011|244